Preparation method of tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA

A chemotherapeutic drug and nanoparticle technology, which can be used in medical preparations with non-active ingredients, medical preparations containing active ingredients, anti-tumor drugs, etc. time, improve curative effect, reduce the effect of toxic and side effects

Active Publication Date: 2018-06-01
宋振川
View PDF5 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Naked siRNA has an extremely short half-life due to the action of nucleases in plasma
Moreover, due to high molecular weight, hydrophilicity, and high charge density, naked siRNA can hardly penetrate cell membranes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA
  • Preparation method of tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA
  • Preparation method of tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] a. After dissolving 18mg polyethyleneimine-lactic acid glycolic acid polymer in 1ml dichloromethane, add 0.2ml deionized water and mix well;

[0026] b. Ultrasonic crush the above solution and emulsify it into a homogeneous emulsion; use the cell disruptor at 25% power for 5 minutes;

[0027] c. After mixing 1.8ml of vinyl alcohol with a mass concentration of 1.8% and 0.2ml of hydrophobic paclitaxel with a mass concentration of 1.8% and 2-4ml of dichloromethane, add it to the above-mentioned emulsion, and then continuously add 10ml of it with a mass concentration of 0.6%. In the state of vinyl alcohol, it was ultrasonically crushed again and then emulsified into a homogeneous emulsion;

[0028] d. After the organic phase in the emulsion prepared in step c is removed with a low-pressure rotary evaporator, the nanoparticle cores loaded with paclitaxel are obtained;

[0029] e. Rinse the paclitaxel-loaded nanoparticle core with deionized water for 5 minutes at 12,000 rpm,...

Embodiment 2

[0036] Embodiment 2: the difference between this embodiment and embodiment 1 is that

[0037] a. After dissolving 20mg polyethyleneimine-lactic acid glycolic acid polymer in 1ml dichloromethane, add 0.25ml deionized water and mix well;

[0038] b. Ultrasonic crush the above solution and emulsify it into a homogeneous emulsion; use the cell disruptor at 25% power for 5 minutes;

[0039] c. After mixing 2.0ml of vinyl alcohol with a mass concentration of 2.0% and 0.25ml of hydrophobic paclitaxel with a mass concentration of 2.0% and 2-4ml of dichloromethane, add it to the above emulsion, and then continuously add 10ml of it with a mass concentration of 0.6%. In the state of vinyl alcohol, it was ultrasonically crushed again and then emulsified into a homogeneous emulsion;

[0040] d. After the organic phase in the emulsion prepared in step c is removed with a low-pressure rotary evaporator, the nanoparticle cores loaded with paclitaxel are obtained;

[0041] e. Rinse the pacli...

Embodiment 3

[0042] Embodiment 3: the difference between this embodiment and embodiment 1 is,

[0043] a. After dissolving 22mg polyethyleneimine-lactic acid glycolic acid polymer in 1ml dichloromethane, add 0.3ml deionized water and mix well;

[0044] b. Ultrasonic crush the above solution and emulsify it into a homogeneous emulsion; use the cell disruptor at 25% power for 5 minutes;

[0045] c. After mixing 1.8-2.2ml of vinyl alcohol with a mass concentration of 2.2% and 0.3ml of hydrophobic paclitaxel with a mass concentration of 2.2% and 2-4ml of dichloromethane, add it to the above-mentioned emulsion, and then continuously add 10ml of it with a mass concentration of In the state of 0.6% vinyl alcohol, it was ultrasonically crushed again and then emulsified into a homogeneous emulsion;

[0046] d. After the organic phase in the emulsion prepared in step c is removed with a low-pressure rotary evaporator, the nanoparticle cores loaded with paclitaxel are obtained;

[0047] e. Rinse th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of a tumor targeted nanoparticle carrier co-loaded with breast cancer chemotherapeutic drug MTDH siRNA. A PEI-PLGA (polyethyleneimine-poly(lactic-co-glycolic acid)) polymer is dissolved in dichloromethane, deionized water is added, the solution is subjected to ultrasonic crushing and emulsified into a homogenous emulsion, vinyl alcohol, hydrophobic taxol and dichloromethane are mixed and added to the emulsion, the mixture is subjected to ultrasonic crushing and emulsified, the emulsion is evaporated, a nanoparticle suspension is obtained, nanoparticle cores coated with taxol are prepared from the nanoparticle suspension, and then, bleaching, stirring and centrifugation are performed. The breast cancer chemotherapeutic drug and nucleic acid are carried into breast cancer tumor cells with high-expression MTDH genes to inhibit cell proliferation and have significant in-vitro and in-vivo tumor targeting. The carrier has clear anti-tumor effects,used carrier materials have high safety, and the carrier has good biocompatibility and biodegradability and has no biotoxicity or immunogenicity. The preparation process is simple, easy to operate, time-saving, energy-saving and suitable for mass production.

Description

technical field [0001] The invention belongs to the field of nano-medicines, and in particular relates to a preparation method of tumor-targeting nano-particles co-carrying breast cancer chemotherapeutic drug MTDH siRNA. technical background [0002] Malignant tumor is an important disease that threatens human health and social development. Its occurrence is a complex process of multi-gene and multi-factor interaction, which eventually leads to abnormal cell proliferation and death. Breast cancer has become the tumor with the highest incidence rate in women, and as a highly heterogeneous tumor, breast cancer has significant differences in pathological typing, molecular typing, and prognosis. Although estrogen receptor-positive breast cancer can benefit from endocrine therapy, chemotherapy still plays an important role in postoperative systemic treatment and treatment of recurrence and metastasis. However, triple-negative breast cancer is highly invasive, prone to recurrence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/69A61K31/337A61K31/713A61P35/00
CPCA61K31/337A61K31/713A61K2300/00
Inventor 宋振川
Owner 宋振川
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap